B-ALL

This phase 2 trial tests an experimental treatment called Senl_B19 CAR-T cells in people aged 3 to 25 whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard therapy. The therapy uses a patient's own immune cells, modified to recognize and atta…

This early-phase study tests a two-step approach for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. First, patients receive a radioactive antibody (131-I apamistamab) to prepare the body, followed by CAR T-cell therapy …

This study tests whether a second type of CAR T-cell therapy, targeting a protein called CD22, can prevent relapse in people with B-cell acute lymphoblastic leukemia who are in remission after initial CD19 CAR T-cell treatment. About 20 participants aged 3 to 65 will receive the …

This early-stage study tests a new drug called KSV01 in 30 adults with a hard-to-treat blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers w…

This study tests a new type of immunotherapy for children and young adults (ages 3-39) with B-cell cancers like leukemia or lymphoma that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to target…

This early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults up to age 21 with certain blood cancers (AML, MDS, ALL, or BPDCN) that have come back or not responded to standard therapy. The treatment involves collecting the patient's own immu…

This study is testing whether a personalized cell therapy (CAR-T) is better than standard chemotherapy at clearing tiny amounts of leftover leukemia cells in patients who have already had a stem cell transplant. The goal is to prevent the cancer from coming back. About 70 patient…

This study follows 100 children and young adults who have received CAR T-cell therapy to learn about short- and long-term side effects. Researchers will track how often patients get infections, have delays in blood cell recovery, or experience nerve damage. The goal is to better …

This study looks at whether frequent blood and bone marrow tests can help doctors know if a child's leukemia will come back after CAR T-cell therapy. About 60 children and young adults aged 1 to 25 who have achieved remission after CAR T-cell therapy will be monitored every two w…